Pay in 4 interest-free payments of $5.52 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
This typically represents increased activity in healing tissues rather than worsening of the condition
Can-Fite BioPharma completed enrollment of the first 247 patients, triggering the pre-specified interim analysis of its pivotal Phase 3 trial (NCT06643260) for piclidenoson, a first-in-class oral A3 adenosine receptor (A3AR) agonist, in moderate-to-severe plaque psoriasis
But real life comes in
Accessed June 18, 2024
Journal of Dermatological Treatment, 23(2), 97-102
Microbes Infection
US$ 29.05
US$ 22.44
US$ 20.45
US$ 20.83
US$ 28.42
